The first domestic insurance benefit for an oral hepatitis C treatment with the ‘shocking’ drug price

An oral hepatitis C treatment will acquire the health insurance benefit for the first time in Korea. The subject of the news is the BMS’s dual therapy of ‘Daklinza(generic name: daclatasvir)’ and ‘Sunvepra(asunaprevir).’

According to a person concerned of the benefit policy, the BMS’s dual therapy of ‘Daklinza(generic name: daclatasvir)’ and ‘Sunvepra(asunaprevir)’ to treat hepatitis C will be...